BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 25, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» INCA-33890, a novel bispecific antibody targeting PD-1 and TGF-ꞵR2
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
INCA-33890, a novel bispecific antibody targeting PD-1 and TGF-ꞵR2
May 8, 2023
No Comments
Researchers from Incyte Corp. presented preclinical characterization of a novel bispecific antibody, INCA-33890, targeting PD-1 and transforming growth factor-β receptor type-2 (TGF-βR2).
BioWorld Science
Conferences
Cancer
Immuno-oncology
